Improving the treatment of Parkinson´s disease

Reference number
Coordinator Lunds universitet - Institutionen för experimentell medicinsk vetenskap, Lund
Funding from Vinnova SEK 2 900 000
Project duration July 2019 - June 2021
Status Ongoing
Venture Swelife and Medtech4Health - Collaborative Projects for Improved Health
Call Swelife and Medtech4Health - Collaborative Projects for Improved Health (Spring 2019)

Purpose and goal

We aim to develop a new therapy that will help ameliorating the troubling side-effects associated with long-term levodopa treatment in PD, affecting the majority of the PD patients. Our main objective is here to characterize the antidyskinetic and antipsychotic properties of a recently developed a new compound (IRL790), by IRL AB. In two detailed animal studies IRL790 will be benchmarked against the best existing drugs used to treat these conditions (amantadine and pimavanserin)

Expected results and effects

By improving the symptomatic treatment of PD, we will increase the quality of life for many of the approxaimtely 20 000 PD patients in Sweden that live with this chronic disease. In particular, we aim to develop a new therapy to treat motor complications and psychosis affecting the majority of late-stage PD patients. The direct costs of patients with PD in Sweden, is estimated to be SEK 1.7 billion, 52% for inpatient care, 27% for outpatient care and 21% for drugs. Reducing the care need in a large fraction of the aptients could help reduced these costs significantly.

Planned approach and implementation

In behavioral experiments, we will compare acute treatment effects but also investigate if IRL790 can help delaying or even preventing the development of LID. We will also apply a novel technology, recently developed by researchers in Lund, that makes it possible to record the brain activity in experimental animals while they are being treated with the different drugs to alleviate symptoms. Thus, for the first time, we will get a direct window into the brain processes causing symptoms of disease, and also the mechanisms of action of the tested drugs.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 May 2019

Reference number 2019-01458

Page statistics